The Effect of Educational Intervention on Adropin Levels and Insulin Resistance in Diabetic Patients

Investigating the efficacy of Self-Care Educational Intervention on Adropin Levels and Insulin Resistance in Type 2 Diabetes Patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160625028627N6

Enrollment

Registered

2025-06-11

Start date

2025-06-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention Group: In addition to the routine care provided at the diabetes clinic, participants in this group will receive a 12-week educational intervention. The educational interve

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Iranian nationality Age 18 years and above Diagnosed with type 2 diabetes for at least 6 months Glycated hemoglobin level of 8% or higher

Exclusion criteria

Exclusion criteria: Complications of type 2 diabetes that disrupt the patient's care process, such as blindness, dialysis, severe stroke Medical history of cognitive disorders like dementia or Alzheimer's Uncontrolled hypertension above 180/110 millimeter of mercury Hearing and visual impairments Hemolytic anemia Hemoglobinopathy

Design outcomes

Primary

Measure	Time frame
Adropin. Timepoint: Evaluation of Mean Adropin Levels Before the Intervention and 3 Months After the Completion of the Intervention. Method of measurement: Blood test using ELISA kit.;Insulin resistance. Timepoint: Assessment of insulin resistance before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using ELISA kit (HOMA-IR index).	—

Secondary

Measure	Time frame
Mean serum triglyceride levels (milligrams per deciliter). Timepoint: Mean Serum triglyceride levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic colorimetric assay kits.;Mean serum total cholesterol levels (milligrams per deciliter). Timepoint: Mean serum total cholesterol levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic colorimetric assay kits.;Mean serum LDL-C levels (milligrams per deciliter). Timepoint: Mean serum LDL-C levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using direct enzymatic assay kits.;Mean serum HDL-C levels (milligrams per deciliter). Timepoint: Mean serum HDL-C levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using homogeneous enzymatic assay kits.;Mean serum BUN levels (milligrams per deciliter). Timepoint: Mean serum BUN levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic kit with urease-glutamate dehydrogenase (GLDH) method.;Mean serum creatinine levels (milligrams per deciliter). Timepoint: Mean serum creatinine levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using an enzymatic kit.;Body mass index. Timepoint: Mean Body mass index levels (kilogram per square meter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Measurements will be performed by trained staff using calibrated digital scales and stadiometers.	—

Measure

Time frame

Mean serum triglyceride levels (milligrams per deciliter). Timepoint: Mean Serum triglyceride levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic colorimetric assay kits.;Mean serum total cholesterol levels (milligrams per deciliter). Timepoint: Mean serum total cholesterol levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic colorimetric assay kits.;Mean serum LDL-C levels (milligrams per deciliter). Timepoint: Mean serum LDL-C levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using direct enzymatic assay kits.;Mean serum HDL-C levels (milligrams per deciliter). Timepoint: Mean serum HDL-C levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using homogeneous enzymatic assay kits.;Mean serum BUN levels (milligrams per deciliter). Timepoint: Mean serum BUN levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using enzymatic kit with urease-glutamate dehydrogenase (GLDH) method.;Mean serum creatinine levels (milligrams per deciliter). Timepoint: Mean serum creatinine levels (milligrams per deciliter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Blood test using an enzymatic kit.;Body mass index. Timepoint: Mean Body mass index levels (kilogram per square meter) before the intervention and 3 months after the completion of the intervention. Method of measurement: Measurements will be performed by trained staff using calibrated digital scales and stadiometers.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Golnaz Azami

Sanandaj University of Medical Sciences

golnaz.azami64@gmail.com+98 87 3366 4664

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026